Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px
Document › Details

Novimmune S.A.. (3/27/17). "Press Release: Novimmune Opens a Branch Office in Basel". Geneva & Basel.

Region Region Basel BS
  Country Switzerland
Organisations Organisation Novimmune S.A.
  Organisation 2 Novimmune S.A., Basel office
Products Product emapalumab (NI-0501)
  Product 2 clinical research
Persons Person Holdener, Eduard (Ed) (Novimmune 201512– CEO before Roche CMO)
  Person 2 Mills, Adrian (Novimmune 201409– CBO before GSK since 2000)

Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs, announced today the opening of its branch office in Basel. The Novimmune premises at Dufourstrasse 11 will host the clinical development team and other functions to progress Novimmune’s lead compound Emapalumab towards filing for a marketing authorisation and its subsequent commercial launch in the US and Europe.

“Novimmune is evolving dynamically and Basel, one of the centers for life sciences in Switzerland, is the ideal complement to our Geneva research and early stage development headquarters. While we continue to build our R&D pipeline in Geneva, we are gathering a strong team in Basel to drive the clinical development of our lead medicine for the treatment of young infants and children suffering from a severe and often life-threatening disease“, says Eduard Holdener, Chairman and CEO of Novimmune.

Emapalumab (NI-0501) is currently in phase 2/3 of clinical development to treat primary Hemo-phagocytic Lymphohistiocytosis HLH, a life-threatening disease of severe hyperinflammation which mainly occurs in children. In June 2016, Emapalumab was declared eligible for PRIME (PRIority MEdicine) status by the European Medicines Agency (EMA), just three months after the US Food and Drug Administration (FDA) had granted Breakthrough Therapy Designation to the same compound.

About Novimmune

Novimmune SA is a privately held, Swiss biopharmaceutical company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer. The company is headquartered in Geneva and runs a branch office in Basel. The company currently employs 130 people. More information is available on the company website at

Adrian Mills
+41 (0) 61 201 13 27

Record changed: 2023-06-05


Picture EBD Group Startup Spotlight at BIO-Europe 2023 650x200px

More documents for Novimmune S.A.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture BIO.NRW Greener Manufacutring Show 2023 Köln 650x300px

» top